{"id":"W3112032975","doi":"10.1016/s2152-2650(20)30789-8","title":"CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Ofatumumab; Rituximab; Chronic lymphocytic leukemia; Idelalisib; Medicine; Refractory (planetary science); Ibrutinib; CD20; Alemtuzumab; Leukemia; Immunology; Antibody; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003346386,0.001298666,0.002218458,0.0007541447,0.0004602081,0.00204791,0.00167179,0.001330034,0.006785837],"category_scores_gemma":[0.001998128,0.0004879164,0.002774461,0.0005347181,0.000821787,0.001431984,0.0007233105,0.004274341,0.001558929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002468275,"about_ca_system_score_gemma":0.002358395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00295459,"about_ca_topic_score_gemma":0.009727584,"domain_scores_codex":[0.9990284,0.0005069103,0.00005264559,0.000109328,0.0001092498,0.0001934675],"domain_scores_gemma":[0.9989522,0.0003261784,0.0001432965,0.00006716824,0.00006507822,0.000446146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6994379,0.008150773,0.004798509,0.00109431,0.003222983,0.0001349524,0.0001405249,0.005365891,0.007213775,0.001244963,0.03607882,0.2331167],"study_design_scores_gemma":[0.663664,0.2378549,0.03273478,0.0006620383,0.006091502,0.0005776034,0.0002181562,0.005189029,0.00630044,0.002133202,0.04441974,0.0001545629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8862144,0.04173061,0.001621021,0.007711152,0.002377592,0.002483253,0.0177805,0.0007687893,0.03931274],"genre_scores_gemma":[0.9331515,0.01344272,0.00435021,0.006062232,0.0009915623,0.001770623,0.02516148,0.0002516401,0.01481783],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006785837,"threshold_uncertainty_score":0.02270091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1310781901293731,"score_gpt":0.3845767634133768,"score_spread":0.2534985732840036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}